Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- FHCC Overlake — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in Washington: - Ascentage Investigative Site #1136 — Edmonds, Washington
- Ascentage Investigative Site #1135 — Issaquah, Washington
- Ascentage Investigative Site #1806 — Seattle, Washington
- Ascentage Investigative Site #1510 — Seattle, Washington
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Washington: - Swedish Medical Center Swedish Cancer Institute First Hill Campus — Seattle, Washington
- Northwest Cancer Specialist, Pc(Us Oncology Research) — Vancouver, Washington
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Washington: - Vista Oncology - East Olympia /ID# 267337 — Olympia, Washington
- Northwest Medical Specialties Tacoma /ID# 266327 — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) …
Sponsor: BeOne Medicines
NCT ID: NCT07277231
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in Washington: - Vista Oncology ( Site 5449) — Olympia, Washington
- Medical Oncology Associates, PS ( Site 5406) — Spokane, Washington
Phase 3 Recruiting Industry
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (C…
Sponsor: CSL Behring
NCT ID: NCT07648264
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 2 Recruiting NIH
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564390
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Washington: - Overlake Medical Center — Bellevue, Washington
- Valley Medical Center — Renton, Washington
- Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06672146
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…
Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Washington: - Dren Investigational Site — Seattle, Washington
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants w…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Washington: - Research Site — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Sponsor: AstraZeneca
NCT ID: NCT06542250
Sites in Washington: - Research Site — Seattle, Washington
Phase 2 Recruiting Industry
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07354074
Sites in Washington: - Seattle Childrens Hospital — Seattle, Washington
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a tra…
Sponsor: Children's Hospital Medical Center, Cincinnati
NCT ID: NCT02143830
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington